Leaflet ROPIVACAINA KABI 2mg / ml solution for injection


Indicated for: local anesthesia

Substance: ropivacaine (local anesthetic)

ATC: N01BB09 (Nervous system | Anesthetics, local | Amides)

Ropivacaine is an amide-type local anesthetic used for regional anesthesia and the management of acute or chronic pain. It works by blocking sodium channels in neuronal membranes, inhibiting nerve impulse transmission and inducing numbness in the treated area.

Ropivacaine is administered via injection, typically during surgical procedures, childbirth, or for postoperative pain management. It is preferred due to its long duration of action and a more favorable safety profile compared to other local anesthetics, with a lower risk of systemic toxicity.

Common side effects include hypotension, nausea, dizziness, and injection site reactions. In rare cases, severe adverse reactions such as systemic toxicity or allergic responses may occur. Administration should be performed by a qualified professional with careful patient monitoring.

Ropivacaine is a safe and effective option for local anesthesia and pain management, enhancing patient comfort in various medical settings.

General data about ROPIVACAINA KABI 2mg / ml

  • Substance: ropivacaine
  • Date of last drug list: 01-08-2023
  • Commercial code: W55681011
  • Concentration: 2mg / ml
  • Pharmaceutical form: solution for injection
  • Packing volume: 20 ml
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: FRESENIUS KABI NORGE AS - NORVEGIA
  • Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA
  • Number: 5862/2013/05
  • Shelf life: 3 years-after packing for marketing;after the first opening-it is used immediately

Concentrations available for ropivacaine

  • 10mg/h
  • 10mg/ml
  • 2mg/ml
  • 5mg/ml
  • 7.5mg/ml